Compare Royal Bank of Canada (RY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Sanofi SA — how do they compare? Royal Bank of Canada trades at $210.44 (market cap $292.92B), while Sanofi SA trades at $43.25 (market cap $104.57B). The key difference: Royal Bank of Canada is far larger — about 2.8× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| RY | SNY | |
|---|---|---|
Market Cap | $292.92B | $104.57B |
Sector | Financials | Health |
52-Week High | $217.87 | $52.34 |
52-Week Low | $134.80 | $41.33 |
Dividend Yield | 2.36% | 5.56% |
Enterprise Value | — | $124.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $211.08, down 0.17% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.84 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. Analyst consensus is mixed, with 43% buy ratings, while recent news highlights insider selling and institutional adjustments to holdings.
RY presents a solid investment case with robust profitability and consistent earnings outperformance, though valuation ratios like P/E of 19.23 and P/B of 3.17 suggest a premium. Risks include high debt levels and macroeconomic sensitivity, but the bullish technical trend and dividend yield support a cautiously optimistic outlook for long-term investors.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
